Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

Basit Öğe Kaydı
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorArtac, Mehmet
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorBozcuk, Hakan
dc.date.accessioned2024-02-23T14:29:37Z
dc.date.available2024-02-23T14:29:37Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC. Methods: A total of 25 patients were retrospectively reviewed. Ifosfamide dose was 1500 mg/m2/ per day, days 1-3, irinotecan 80 mg/m2 per day days 1.8 and 15 every four weeks. Results: Median age of patients was 55 years (range 42-80). Median chemotherapy cycles were 3 (range 1-7). The frequency of the second, third and fourth line treatments were 68%, 24%, and 8% respectively. Partial remission was obtained in 15 patients (60%) and complete remission in one patient (4%). Median progression free survival (PFS) and overall survival (OS) figures were 7.8 and 11.1 months, respectively. Granulocyte colony stimulating factor (G-CSF) was used in 40% of patients. Grade 3-4 anemia, leukopenia, and thrombocytopenia were seen in 20%, 36% and 12% of these cases, respectively. Conclusion: Ifosfamide and irinotecan combination is an effective and a tolerable treatment option for patients with platinum refractory SCLC.en_US
dc.identifier.doi10.14744/ejmo.2020.15578
dc.identifier.endpage176en_US
dc.identifier.issn2587-196X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85163016350en_US
dc.identifier.startpage172en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2020.15578
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14774
dc.identifier.volume4en_US
dc.identifier.wosWOS:000604253900011en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectIfosfamideen_US
dc.subjectIrinotecanen_US
dc.subjectSmall Cell Lung Canceren_US
dc.subjectSurvivalen_US
dc.titleIrinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu